CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 145 enrolled
Drug / intervention
AN2728 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01029405
NCT01029405Phase 2Completed

A Double-Blind,Randomized, 12 Week, Bilateral Study of the Safety and Efficacy of AN2728 Ointment B, 2% and 0.5%, Versus Ointment B Vehicle in the Treatment of Patients With Plaque Type Psoriasis

Pfizer·interventional·Posted Dec 10, 2009·Updated Mar 7, 2017

In Brief

A Phase 2 clinical trial evaluating AN2728 and Placebo for Psoriasis. Completed, enrolled 145 participants across 5 sites.

Detailed Summary

The purpose of this study is to evaluate the safety and efficacy of AN2728 Ointment B, 2.0% and 0.5%, compared to Ointment Vehicle B, applied once or twice daily for 12 weeks, in the treatment of plaque type psoriasis

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesMexico
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 10, 2009
Enrollment StartNov 1, 2009
Primary CompletionMay 1, 2010
Study CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 16.6 years ago

Interventions

AN2728drug

Ointment B, 2% or 0.5% applied once or twice daily

Placebodrug

Ointment B Vehicle applied once or twice daily